CA
NZ
UK
AU
IND
US
Falcon's Beyond Global, Inc. filed its Form 10-Q with the SEC on August 13, 2026, covering the quarterly period ended June 30, 2026, and reporting 49,089,498 shares of Class A common stock and 72,169,750 shares of Class B common stock issued and outstanding as …
Bit Digital, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 13, 2026, announcing the release of its second quarter 2026 financial results and the holding of an earnings conference call on the same date.
Cabaletta Bio, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the period ended June 30, 2026, disclosing significant losses, a going concern warning, and ongoing clinical-stage operations centered on its lead product candidate resecabtagene autoleucel.
CorMedix Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission on August 13, 2026, reporting net income of $25,988 thousand for the second quarter.
SS Innovations International, Inc. filed a Current Report on Form 8-K with the SEC on August 13, 2026, announcing financial results for the three and six month periods ended June 30, 2026, along with the concurrent filing of its quarterly report for that period.
Accelerant Holdings filed a Form 8-K on August 13, 2026, disclosing second-quarter 2026 earnings results and announcing the execution of a merger agreement with affiliates of Thoma Bravo.
Accelerant Holdings filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the period ended June 30, 2026, as reported on August 13, 2026.
SS Innovations International, Inc. filed its quarterly report on Form 10-Q with the SEC on August 13, 2026, covering the three and six months ended June 30, 2026.
Ovid Therapeutics Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on August 13, 2026, covering the quarterly period ended June 30, 2026, disclosing the company's financial condition and operations as a non-accelerated, smaller reporting company listed on NASDAQ:OVID.
Candel Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing its financial condition, operational status, and risk factors as of that date.
Please wait processing your request...